« Back to Record
Citation APA

Puoti, M., Foster, G. R., Wang, S., Mutimer, D., Gane, E., Moreno, C., Chang, T. T., Lee, S. S., Marinho, R. T., Dufour, J. F., Pol, S., Hezode, C., Gordon, S. S., Strasser, S., Thuluvath, P. J., Zhang, Z., Lovell, S., Pilot-Matias, T., & Mensa, F. F. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of hepatology, 69(2), 293-300. doi:10.1016/j.jhep.2018.03.007


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/286529

Puoti, M., Foster, G. R., Wang, S., Mutimer, D., Gane, E., Moreno, C., Chang, T. T., Lee, S. S., Marinho, R. T., Dufour, J. F., Pol, S., Hezode, C., Gordon, S. S., Strasser, S., Thuluvath, P. J., Zhang, Z., Lovell, S., Pilot-Matias, T., & Mensa, F. F. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of hepatology, 69(2), 293-300. doi:10.1016/j.jhep.2018.03.007